Products
Fiztasovimab Biosimilar Monoclonal Antibody (Herpesvirus Glycoprotein B AD-1) for Research
Cat No.: GMP-Bios-INN-1206
Anti-Human Herpesvirus Glycoprotein B AD-1 therapeutic antibody (Pre-made Fiztasovimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Fiztasovimab (development code NPC-21) is a monoclonal antibody targeting human betaherpesvirus 5 (cytomegalovirus). It is developed by Nobelpharma Co for cytomegalovirus infections. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1206-1mg | 1mg | 3090 |
| GMP-Bios-INN-1206-10mg | 10mg | |
| GMP-Bios-INN-1206-100mg | 100mg | |
| GMP-Bios-INN-1206-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Fiztasovimab biosimilar, Whole mAb: Anti-Human Herpesvirus Glycoprotein B AD-1 therapeutic antibody |
| INN Name | Fiztasovimab |
| Target | Human Herpesvirus Glycoprotein B AD-1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Nobelpharma Co |
| Conditions Approved | na |
| Conditions Active | Cytomegalovirus infections |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
